secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2025-07-11T23:59:59+00:00
Accession:  0001193125-25-158211
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma amends CSO Kastelein's employment agreement with enhanced severance
--------------------------------------------------------------------------------

- Amended agreement effective July 1, 2025; replaces November 2022 pact.
- Termination without cause entitles Kastelein to 12 months base salary, earned bonus, and prorated annual bonus.
- Change-in-control trigger: same severance plus acceleration of all time-based stock options and equity awards.
- Exercise period for certain vested options extended upon qualifying termination.
- Kastelein remains Chief Scientific Officer and a director; no departure announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312525158211/0001193125-25-158211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312525158211/d915297d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-158211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer